ArticleGynecologic oncology2022
Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States.
Article in Gynecologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Disparities in Human Papillomavirus Vaccination and Cervical Cancer Prevention and Screening Strategies: A Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Barriers to cancer screening uptake and approaches to overcome them: a systematic literature review.Frontiers in oncology · 2025Pooled it
- Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.Nature communications · 2026Trial
- Differential diagnostic value of PAX1 and JAM3 methylation for cervical intraepithelial neoplasia between premenopausal and postmenopausal women: a retrospective clinical study in China.Annals of medicine · 2026Article
- Treatment Patterns and Prognosis of Cervical Cancer Patients Aged 65 and Older: A Population-Based Cohort Study.Annals of surgical oncology · 2026Article
- Clinical translation of a DWI-radiomics nomogram integrating serum biomarkers for pretreatment staging of cervical cancer.BMC medical imaging · 2026Article
- Diagnostic utility and tissue localization of HPV16 and HPV18 E7 immunohistochemistry in cervical lesion progression: a comparative study with PCR.Frontiers in oncology · 2026Article
- Article
- Accelerating the elimination of global cervical cancer through intelligent training for colposcopy.Cancer biology & medicine · 2025Article
- Assessing high-risk human papillomavirus-based cervical precancer screening recommendations and implications among women aged 60/65 years and older in Ghana.Scientific reports · 2025Article
- Sociodemographic inequities in overall survival among younger and older women with cervical cancer.Cancer causes & control : CCC · 2025Article
- Development and validation of the competing risk nomogram and risk classification system for predicting cancer-specific mortality in patients with cervical adenosquamous carcinoma treated via radical hysterectomy.Biomolecules & biomedicine · 2025Article
- Cervical Cancer 2010-2019: An Upper Midwest Catchment of 40,000 Square Miles.Journal of lower genital tract disease · 2025Article
- Exploring the Clinical Signatures of Cervical Dysplasia Patients and Their Association With Vaginal Microbiota.Cancer medicine · 2024Article
- Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review.Biomedicines · 2024Review
- Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors.Gynecologic oncology · 2024Article
- Increasing physical activity among older adults with gynecologic cancers: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Article
- Article
- Epidemiology of cervical cancer in elderly women: Analysis of incidence, treatment, and survival using German registry data.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveGiven that cervical cancer incidence rates do not decline in women >65, there is generally limited screening, and these women have a poor prognosis, it is imperative to better understand this population. We aim to describe the characteristics, treatment, and survival of women >65 diagnosed with cervical cancer.
methodsSEER-Medicare 2004-2013 data was used to describe 2274 patients >65 diagnosed with cervical cancer. Five-year cancer-specific survival was estimated using the Kaplan-Meier method. Multivariable Poisson and Cox regression analyses identified characteristics associated with treatment and mortality.
resultsThe median age was 76.1 years, with nearly one-third of cases occurring in women >80 years. Most patients were non-Hispanic White (64.8%), had comorbidity scores ≥ 1 (53.9%) and squamous histology (66.3%). Most women were diagnosed at stage II or higher (62.7%), including nearly one-quarter at Stage IV (23.1%). Nearly 15% of patients were not treated (14.6%). Lack of treatment was associated with oldest age (>80), comorbidity scores ≥3, and stage IV disease. Five-year cancer-specific survival was 50%. Increasing age and stage at diagnosis were significantly associated with lower cancer-specific survival whereas treatment was strongly associated with increased survival.
conclusionMost women >65 with cervical cancer are diagnosed with locally advanced or metastatic disease and many do not receive treatment. Survival is improved with early-stage diagnosis and treatment. These findings, coupled with the fact that women >65 constitute an increasing proportion of the population, highlight the need to re-evaluate screening and treatment practices in this population to detect cervical cancer at earlier stages and increase survival. NOVELTY AND IMPACT STATEMENT: In SEER-Medicare linked data from 2004 to 2013, most women >65 with cervical cancer were diagnosed with locally advanced or metastatic disease. Both receipt of treatment and survival decreased with increasing age. These findings, coupled with the fact that women aged >65 constitute an increasing proportion of the population, highlight the need to re-evaluate screening and treatment practices in older women to detect cervical cancer at earlier stages and increase survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.